Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Zogenix Inc. : Trading of Zogenix Common Stock Halted

12/07/2012 | 08:00am US/Eastern
Recommend:
0

FDA Advisory Committee Reviewing Zohydro™ ER New Drug Application

Zogenix to Host Conference Call at 6:30 pm ET Today

SAN DIEGO, Dec. 7, 2012 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced that NASDAQ halted trading of the company's common stock on December 7, 2012. The U.S. Food and Drug Administration's (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting today to review the Company's New Drug Application (NDA) for Zohydro™ ER (hydrocodone bitartrate extended-release capsules).

Conference Call & Webcast

Zogenix will host a conference call to discuss the outcome of the AADPAC meeting today, Friday, December 7, 2012 at 6:30 p.m. ET (3:30 p.m. PT). To participate, please dial (800) 299-9086 (U.S.) or (617) 786-2903 (International); participant passcode: 21970283. To access the live webcast please visit the Zogenix Investor Relations website at http://ir.zogenix.com.  

The conference call will be hosted by Chief Executive Officer Roger L. Hawley and President and Chief Operating Officer Stephen J. Farr, Ph.D.

A replay of the conference call will be available beginning December 7, 2012 at 8:30 p.m. ET (5:30 p.m. PT) until December 14, 2012, by dialing (888) 286-8010 (U.S.) or (617) 801-6888 (International); passcode: 27116437. A replay of the webcast will also be accessible on the Investor Relations website for one month, through January 10, 2013.

About Anesthetic and Analgesic Drug Products Advisory Committee

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed and investigational human anesthetic and analgesic drug products and makes appropriate recommendations to the Commissioner of Food and Drugs. The AADPAC provides FDA with independent expert advice and recommendations, however, the final decision regarding approval is made by FDA.

About Zogenix

Zogenix, Inc., with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL® DosePro® (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead investigational product candidate, ZohydroTM ER (hydrocodone bitartrate) is an oral, novel extended-release formulation of various strengths of hydrocodone without acetaminophen intended for administration every 12 hours for around the clock management of moderate to severe chronic pain. Zogenix's second DosePro investigational product candidate, ReldayTM, is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia. In May 2012, Zogenix submitted to the FDA a New Drug Application for Zohydro ER and an Investigational New Drug Application for Relday. The FDA assigned a PDUFA target action date of March 1, 2013 for the Zohydro ER NDA.

For additional information, please visit www.zogenix.com.

SUMAVEL ®, DosePro ®, ReldayTM and ZohydroTM ER are trademarks of Zogenix, Inc.

CONTACT: INVESTORS:
         Zack Kubow | The Ruth Group
         646.536.7020 | zkubow@theruthgroup.com

         MEDIA:
         Emily Poe | WCG
         212.301.7183 | epoe@wcgworld.com
Zogenix
distributed by
Recommend :
0
React to this article
Latest news
Date Title
<1m ago AUTONATION : Announces Highest Quarterly Reported Retail New Vehicle Unit Sales since Q3 2006(1)
3m ago BETA SYSTEMS SOFTWARE : IT Security Concerns Top Management Too: Beta Systems Presents Comprehensive Identity & Access Management Portfolio at it-sa 2014 Show
3m ago NATIONAL EXPRESS : Blocklisting Interim Review
3m ago COMPUGROUP MEDICAL : CGM acquires Labelsoft and strengthens its market position in the Dutch market for primary care information systems
3m ago OSIM : Closing Announcement For S$170,000,000 Convertible Bonds Due 2019
3m ago OSIM : S$170,000,000 Convertible Bonds Due 2019
3m ago BANYAN TREE : Purchase of additional shares in Beruwela Walk Inn PLC
3m ago WAH SEONG BHD : Notice of Shares Buy Back by a Company pursuant to Form 28A
3m ago INDIAN OIL : IndianOil's Commitment towards 'Swachh Bharat Mission'
3m ago RESEARCH AND MARKETS : T-Cell Lymphomas Market 2014-2015 - API Manufacturers and Phase III Pipeline Assessment
Latest news
Advertisement
Hot News 
ORDINA : investigates Zembla claims: initial findings reveals no irregularities
INTERQUEST : Recruitment in Tunbridge Wells highlighted in Recruitment International
MASIMO : Philips Electronics to appeal ruling in $467 million patent lawsuit
SAIPEM : awarded new offshore E&C contracts in the Gulf of Mexico totalling $750 million
SONOVA : completes acquisition of Comfort Audio
Most Read News
1d ago JANUS CAPITAL : Pimco Total Return Fund posts record $23.5 billion net outflow in September
6h ago TESLA MOTORS : Musk says 'about time to unveil the D and something else'
1d ago JPMORGAN CHASE : to Present at the Bank of America Merrill Lynch Banking & Financial Services Conference
1d ago CANADIAN PACIFIC RAILWAY : CP Rail looks to boost revenue to C$10 billion in 2018
1d ago TOTAL SYSTEM SERVICES : Pimco Total Return Fund posts record $23.5 billion net outflow in September
Most recommended articles
4m agoDJTESCO : Loomis Gets Deal to Service Tesco's ATMs Throughout UK
5m ago Oslo 2022 Winter Olympics pullout no blow but changes needed - IOC
8m agoDJSAAB : Gets Order to Fit Healthcare Capability to Norwegian Navy Vessel
10m ago BAYERISCHE MOTOREN WERKE : BMW sees 2014 passenger car sales growing 3-4 percent
13m ago China likely to have annual growth of at least 7 percent for years - ADB
Dynamic quotes  
ON
| OFF